SEC Form 4 · accession 0001179110-15-005436
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J. Mulroy
Officer — President and CEO · Director
Period of report
Mar 23, 2015
Accepted (ET)
Mar 25, 2015 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 23, 2015 | M | 10,400 | $1.71 | A | 1,349,716 | D | |
| Common StockF1 | Mar 23, 2015 | S | 10,400 | $11.69 | D | 1,339,316 | D | |
| Common Stock | Mar 24, 2015 | M | 273,968 | $1.71 | A | 1,613,284 | D | |
| Common StockF2 | Mar 24, 2015 | S | 103,968 | $11.71 | D | 1,509,316 | D | |
| Common Stock | Mar 24, 2015 | M | 52,985 | $2.47 | A | 1,562,301 | D | |
| Common Stock | Mar 24, 2015 | M | 26,689 | $2.59 | A | 1,588,990 | D | |
| Common Stock | Mar 24, 2015 | M | 94,338 | $2.12 | A | 1,683,328 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.71 | Mar 23, 2015 | M | 10,400 | D | — | Aug 3, 2015 | Common Stock | 10,400 | 273,968 | D |
| Stock Option (right to buy)F3 | $1.71 | Mar 24, 2015 | M | 273,968 | D | — | Aug 3, 2015 | Common Stock | 273,968 | 0 | D |
| Stock Option (right to buy)F3 | $2.47 | Mar 24, 2015 | M | 52,985 | D | — | Jan 23, 2017 | Common Stock | 52,985 | 0 | D |
| Stock Option (right to buy)F3 | $2.59 | Mar 24, 2015 | M | 26,689 | D | — | Oct 4, 2017 | Common Stock | 26,689 | 0 | D |
| Stock Option (right to buy)F3 | $2.12 | Mar 24, 2015 | M | 94,338 | D | — | Nov 5, 2019 | Common Stock | 94,338 | 680,662 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.65 to $11.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.50 to $11.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3This option is fully vested.